Clinical significance of novel costimulatory molecule B7-H6 in human breast cancer

Sun,Jing; Tao,Hong; Li,Xiaoning; Wang,Lu; Yang,Jie; Wu,Pingping; Zhang,Yaqin; Guo,Yundi

doi:10.3892/ol.2017.6417

Clinical significance of novel costimulatory molecule B7-H6 in human breast cancer

Authors:
- Jing Sun
- Hong Tao
- Xiaoning Li
- Lu Wang
- Jie Yang
- Pingping Wu
- Yaqin Zhang
- Yundi Guo
View Affiliations

Affiliations: Institute of Medical Biotechnology, Suzhou Vocational Health College, Suzhou, Jiangsu 215009, P.R. China, Department of Pathology, The Fourth Affiliated Hospital of Nanjing Medical University, Suzhou, Jiangsu 214062, P.R. China
Published online on: June 19, 2017 https://doi.org/10.3892/ol.2017.6417
Pages: 2405-2409

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

B7 homolog 6 (B7-H6), a member of the B7 family, is as a cell-surface ligand for natural cytotoxicity triggering receptor 3, which is expressed on natural killer cells. It has previously been reported that B7‑H6 is undetectable in normal human tissues but is expressed on tumor cells. However, there are few studies focusing on the clinical significance of B7‑H6 expression in human carcinoma, with the exception of three studies on ovarian, lung and gastric cancer. The present study investigated the expression of B7‑H6 protein in pathologic tissue samples from 305 patients with breast cancer using immunohistochemistry. A high B7‑H6 expression level was identified in tissues from 32.13% of patients with breast cancer. These patients were revealed to also exhibit a high expression level of human epidermal growth factor receptor 2, a shorter survival time and a higher rate of lymph node metastasis. Furthermore, the expression level of B7‑H6 was not associated with patient age, breast cancer subtype, tumor size, tumor location or estrogen receptor expression. The results of the present study revealed that higher B7‑H6 expression level in breast cancer tissues was positively associated with tumor progression. This indicates that B7‑H6 is associated with the progression and immunoevasion of human breast cancer; however, the molecular mechanisms underlying this potential effect require further investigation.

View Figures

View References

1	Brandt CS, Baratin M, Yi EC, Kennedy J, Gao Z, Fox B, Haldeman B, Ostrander CD, Kaifu T, Chabannon C, et al: The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med. 206:1495–1503. 2009. View Article : Google Scholar : PubMed/NCBI
2	Xu X, Narni-Mancinelli E, Cantoni C, Li Y, Guia S, Gauthier L, Chen Q, Moretta A, Vély F, Eisenstein E, et al: Structural insights into the inhibitory mechanism of an Antibody against B7-H6, a stress-induced cellular ligand for the natural killer cell receptor NKp30. J Mol Biol. 428:4457–4466. 2016. View Article : Google Scholar : PubMed/NCBI
3	Pesce S, Tabellini G, Cantoni C, Patrizi O, Coltrini D, Rampinelli F, Matta J, Vivier E, Moretta A, Parolini S and Marcenaro E: B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape. Oncoimmunology. 4:e10012242015. View Article : Google Scholar : PubMed/NCBI
4	Vivier E, Tomasello E, Baratin M, Walzer T and Ugolini S: Functions of natural killer cells. Nat Immunol. 9:503–510. 2008. View Article : Google Scholar : PubMed/NCBI
5	Bretscher P and Cohn M: A theory of self-nonself discrimination. Science. 169:1042–1049. 1970. View Article : Google Scholar : PubMed/NCBI
6	Flies DB and Chen L: The new B7s: Playing a pivotal role in tumor immunity. J Immunother. 30:251–260. 2007. View Article : Google Scholar : PubMed/NCBI
7	Hurwitz AA, Kwon ED and van Elsas A: Costimulatory wars: The tumor menace. Curr Opin Immunol. 12:589–596. 2000. View Article : Google Scholar : PubMed/NCBI
8	Mahoney KM and Atkins MB: Prognostic and predictive markers for the new immunotherapies. Oncology (Williston Park). 28 Suppl 3:S39–S48. 2016.
9	Mahoney KM, Freeman GJ and McDermott DF: The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clin Ther. 37:764–782. 2015. View Article : Google Scholar : PubMed/NCBI
10	Ceeraz S, Nowak EC and Noelle RJ: B7 family checkpoint regulators in immune regulation and disease. Trends Immunol. 34:556–563. 2013. View Article : Google Scholar : PubMed/NCBI
11	Matta J, Baratin M, Chiche L, Forel JM, Cognet C, Thomas G, Farnarier C, Piperoglou C, Papazian L, Chaussabel D, et al: Induction of B7-H6, a ligand for the natural killer cell-activating receptor NKp30, in inflammatory conditions. Blood. 122:394–404. 2013. View Article : Google Scholar : PubMed/NCBI
12	Zhang X, Zhang G, Qin Y, Bai R and Huang J: B7-H6 expression in non-small cell lung cancers. Int J Clin Exp Pathol. 7:6936–6942. 2014.PubMed/NCBI
13	Chen XJ, Shen J, Zhang GB and Chen WC: B7-H6 protein expression has no prognostic significance in human gastric carcinoma. Pathol Oncol Res. 20:203–207. 2014. View Article : Google Scholar : PubMed/NCBI
14	Zhou Y, Xu Y, Chen L, Xu B, Wu C and Jiang J: B7-H6 expression correlates with cancer progression and patient's survival in human ovarian cancer. Int J Clin Exp Pathol. 8:9428–9433. 2015.PubMed/NCBI
15	Chen L, Deng H, Lu M, Xu B, Wang Q, Jiang J and Wu C: B7-H1 expression associates with tumor invasion and predicts patient's survival in human esophageal cancer. Int J Clin Exp Pathol. 7:6015–6023. 2014.PubMed/NCBI
16	Seliger B and Quandt D: The expression, function, and clinical relevance of B7 family members in cancer. Cancer Immunol Immunother. 61:1327–1341. 2012. View Article : Google Scholar : PubMed/NCBI
17	Lu B, Chen L, Liu L, Zhu Y, Wu C, Jiang J and Zhang X: T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract. Immunol Res. 50:269–275. 2011. View Article : Google Scholar : PubMed/NCBI
18	Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al: Safety, activity and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
19	Kaifu T, Escalière B, Gastinel LN, Vivier E and Baratin M: B7-H6/NKp30 interaction: A mechanism of alerting NK cells against tumors. Cell Mol Life Sci. 68:3531–3539. 2011. View Article : Google Scholar : PubMed/NCBI
20	Guo JG, Guo CC, He ZQ, Liu ZG, Wang Y and Mou YG: Clinical significance of B7-H6 protein expression in astrocytoma. Onco Targets Ther. 9:3291–3297. 2016. View Article : Google Scholar : PubMed/NCBI
21	Fiegler N, Textor S, Arnold A, Rölle A, Oehme I, Breuhahn K, Moldenhauer G, Witzens-Harig M and Cerwenka A: Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood. 122:684–693. 2013. View Article : Google Scholar : PubMed/NCBI
22	Joyce MG, Tran P, Zhuravleva MA, Jaw J, Colonna M and Sun PD: Crystal structure of human natural cytotoxicity receptor NKp30 and identification of its ligand binding site. Proc Natl Acad Sci USA. 108:pp. 6223–6228. 2011; View Article : Google Scholar : PubMed/NCBI
23	von Strandmann E Pogge, Simhadri VR, von Tresckow B, Sasse S, Reiners KS, Hansen HP, Rothe A, Böll B, Simhadri VL, Borchmann P, et al: Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity. 27:965–974. 2007. View Article : Google Scholar : PubMed/NCBI
24	Sasaki T, Gan EC, Wakeham A, Kornbluth S, Mak TW and Okada H: HLA-B-associated transcript 3 (Bat3)/Scythe is essential for p300-mediated acetylation of p53. Genes Dev. 21:848–861. 2007. View Article : Google Scholar : PubMed/NCBI
25	Correia DV, Fogli M, Hudspeth K, da Silva MG, Mavilio D and Silva-Santos B: Differentiation of human peripheral blood Vδ11+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells. Blood. 118:992–1001. 2011. View Article : Google Scholar : PubMed/NCBI
26	Delahaye NF, Rusakiewicz S, Martins I, Ménard C, Roux S, Lyonnet L, Paul P, Sarabi M, Chaput N, Semeraro M, et al: Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med. 17:700–707. 2011. View Article : Google Scholar : PubMed/NCBI
27	Schlecker E, Fiegler N, Arnold A, Altevogt P, Rose-John S, Moldenhauer G, Sucker A, Paschen A, von Strandmann EP, Textor S and Cerwenka A: Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30. Cancer Res. 74:3429–3440. 2014. View Article : Google Scholar : PubMed/NCBI
28	Kellner C, Maurer T, Hallack D, Repp R, van de Winkel JG, Parren PW, Valerius T, Humpe A, Gramatzki M and Peipp M: Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity. J Immunol. 189:5037–5046. 2012. View Article : Google Scholar : PubMed/NCBI
29	Semeraro M, Rusakiewicz S, Minard-Colin V, Delahaye NF, Enot D, Vély F, Marabelle A, Papoular B, Piperoglou C, Ponzoni M, et al: Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. Sci Transl Med. 7:283ra2552015. View Article : Google Scholar